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Abstract 
Small fresh water fishes such as the zebrafish (Danio rerio) have become 
important model organisms for biomedical research. They currently represent the best 
vertebrate embryo models in which it is possible to derive quantitative data on gene 
expression, signalling events and cell behavior in real time in the living animal. 
Relevant phenotypes in fish mutants are similar to those of other vertebrate models 
and human diseases. They can be analysed in great details and much faster than in 
mammals. In recent years, approximately 2,500 genetically distinct fish lines have 
been generated by European research groups alone. Their potential, including their 
possible use by industry, is far from being exploited. 
To promote zebrafish research in Europe, EuFishBioMed was founded and 
won support by the EU COST programme (http://www.cost.esf.org/). The main 
objective of EuFishBioMed is to establish a platform of knowledge exchange for 
research on small fish models with a strong focus on widening its biomedical 
applications and an integration of European research efforts and resources. 
EuFishBioMed currently lists more than 300 member laboratories in Europe, offers 
funding for short-term laboratpry visits, organizes and co-sponsors meetings and 
workshops and has successfully lobbied for the establishment of a European Zebrafish 
Resource Centre. To maintain this network in the future, beyond the funding period of 
the COST Action, we are currently establishing the European Society for Fish Models 
in Biology and Medicine.   
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Background 
Small freshwater fishes such as zebrafish (Danio rerio) are increasingly being 
used as model organisms for biomedical research offering sequenced genomes and a 
rich repertoire of genetic, molecular and cellular manipulation tools
1, 2
. A unique set 
of properties (small size, numerous offspring, optical transparency of the embryo, 
amenability to genetic and chemical screens) has made them popular vertebrate 
animal models
2, 3
. It has become clear that the potential of small fish models far 
exceeds their traditional usage in the fields of cell biology and developmental 
genetics. Zebrafish models have been described for a large number of human 
conditions including, but not limited to, polycystic kidney disease
4, 5
, heart 
arrhythmias
6
, congenital heart defects and cardiomyopathies
7
 and myopathies of the 
skeletal musculature
8
, anaemias
9, 10
, cholesterol processing
11
, Waardenburg 
syndrome
10
, Hirschsprung disease
12
, glaucoma
13
, cancer
14
, neurological and 
psychatric disorders
15-17
, tissue regeneration
18
, congenital and acquired deafness
10, 19
, 
neural and retinal degeneration
20, 21
 as well as infectious diseases
22, 23
. In some cases, 
a novel disease gene was discovered first in the zebrafish and only subsequently a 
human disease was linked to it, such as the iron transporter ferroprotein gene in 
haemochromatosis type 4, a disorder in iron metabolism leading to anaemia in 
humans
24
. Thus, zebrafish are not only excellent models for deciphering the 
pathophysiology of human diseases but serve also as effective tools to discover new 
human disease genes (for example
25
).  
 
In addition, small fish models are ideal for generating and experimentally 
validating large data-sets in vivo, making them particularly suited to the genome-wide 
approaches favored by systems biology
26
. By capitalizing on their transparency, the 
small size of the embryos, the ease of introducing markers and the possibility of 
achieving optical resolution at cellular and sub-cellular level, these small fishes 
provide vertebrate models that allow analysis of development and organ formation at 
a systems level in living organisms
27, 28
. Such processes can be studied against the 
disturbances introduced by genetic mutations and chemicals eventually allowing the 
integration of data into a virtual model of a vertebrate embryo. 
 
The zebrafish is attracting increasing attention from the pharmaceutical 
industry as it is highly amenable to whole animal drug screening
29
 and toxicological 
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studies
30-32
. First examples have already appeared in the literature where drug 
candidates were successfully identified by screening for suppression of complex 
genetic defects (phenotypic rescue) in zebrafish embryos
33
. In Germany, the zebrafish 
embryo toxicity assay has become a DIN standard for testing the water quality of 
sewage plants
34
. Moreover, molecular studies suggest that the zebrafish embryo may 
offer a suitable alternative model for systematic testing of chemicals under the 
European REACH initiative
35
. 
 
The rising interest in this field is encouraging an increasing number of 
researchers within the biomedical community to consider using small fish. However, 
the highly fragmented research endeavor and a limited awareness of the specific 
research topics pursued by each European laboratory, leaves a lot to be improved with 
respect to concerted scientific approaches and strategies. Moreover, the full potential 
of zebrafish has only started to be recognized in the industrial and regulatory sector. 
To overcome this, we have established the European Network on Fish Biomedical 
Models (EuFishBioMed) and successfully applied for sponsoring by the EU COST 
programme (http://www.cost.eu/domains_actions).  
 
EuFishBioMed, the European network of zebrafish researchers 
The necessity for a European network of zebrafish researcher was recognized 
in discussions held at a break-out session of the 5th European Zebrafish Meeting in 
Amsterdam, in 2007. In particular, the complex funding structure in Europe with both 
national and centralized European resources demanded a visible Europe-wide 
organisation that could lobby for funding opportunities and infrastructure for 
zebrafish research. From the beginning, it was clear that this network should not only 
include researchers working with zebrafish but also laboratories using other small fish 
species in their biomedically oriented research, such as medaka and swordtail. The 
European COST programme (http://www.cost.eu/domains_actions) with its aim of 
fostering scientific collaboration across Europe appeared most appropriate for funding 
of such an initiative. By winning support through a COST Action for the years 2009 
to 2013, the European zebrafish community was endowed with the resources to firmly 
establish the networking infrastructure of EuFishBioMed.     
 
One of the objectives of EuFishBioMed is to promote research on and use of 
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small fish as models for human diseases by providing a communication platform. To 
this end, a website was established at the Institute of Toxicology and Genetics (ITG) 
of the Karlsruhe Institute of Technology (KIT). The database of EuFishBioMed lists 
353 principal investigators from 23 European countries as network members. 
Interested parties from outside of Europe are welcome too: in particular colleagues 
from Australia and New Zealand eagerly subscribed to the information network, with 
both countries being partners in the COST programme. In addition, we count 
members from India, Chile, Singapore, USA and Japan. 
 
Lobby work to promote Europe-wide standardized protocols for fish 
husbandry as well as regulatory guidelines concerning experimental work with these 
fish models (
31
 and http://eufishbiomed.kit.edu) is an on-going activity of 
EuFishBioMed. This is particularly important in view of the differences in national 
and regional regulatory guidelines in Europe.  For example even within Germany, 
different regulatory opinions exist as to when a zebrafish is regarded as an animal and 
when experimentation should thus be subject to approval by the authorities. 
EuFishBioMed has gained an important role as competent advisor and authority in 
these matters across Europe
31
.  
 
EuFishBioMed has been organising workshops and meetings (Table 1) to 
bring together leading experts in the field and to allow young researchers and 
investigators to get insight into research with fish models. Topics covered by these 
meetings have ranged from sperm freezing, neurobiology, behavioral analysis and 
disease models to automation and digital image processing. To foster strategic 
discussions, we have established a European Zebrafish Principal Investigator Meeting 
(EZPM), an international meeting for principal investigators from all over the world
36
. 
This meeting takes place every two years alternating with the Strategic Conference of 
Zebrafish Investigators in Asilomar, USA. An additional important objective is the 
outreach to the wider biomedical research community, to industry and regulators to 
facilitate translation of zebrafish research into medical and industrial applications. To 
this end, workshops on disease models or specific applications such as toxicology 
have been held with participants from interested parties outside the zebrafish field 
(Table 1).  
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Lectures are well suited for information exchange but fail to teach manual 
skills. One of the main aims of EuFishBioMed was to enhance the transfer of 
technology between zebrafish research groups and make experimental protocols 
available to groups new to fish research. EuFishBioMed therefore also co-sponsors 
training schools and funds short term scientific missions (i.e. visits of graduate 
students and postdocs) to laboratories in Europe to learn zebrafish techniques with 
relevance for the research in the home laboratory. This offer is specifically available 
for young researchers. So far, the COST Action EuFishBioMed has funded 27 travel 
grants. This instrument has turned out to be a most effective motor for research 
collaborations across Europe and at the same time efficiently promotes the scientific 
training of early stage researchers.   
 
Establishment of a European Zebrafish Resource Center 
An additional important aim of EuFishBioMed is to lobby for national and 
European funding and to develop the necessary infrastructure for the use of fish 
models in biomedical research in Europe. Several white papers were written and 
submitted to national as well as European funding bodies 
(http://eufishbiomed.kit.edu/eufishbiomed/eufish_downloads.htm). These papers 
highlight research areas to which zebrafish can specifically contribute as a model. 
  
A specific deficit in Europe has been the lack of a centralized infrastructure to 
maintain and distribute zebrafish lines and mutants.  In recent years, approximately 
2,500 mutant and transgenic lines were generated by European research groups, 
mostly in large mutagenesis screens organised as part of the ZF-MODELS project 
(http://zf-health.org/zf-models/information/contact.html). The potential of these fish 
lines including their possible use by the biotechnology industry is far from being 
exploited. Most of these lines are still kept in the labs in which they were created. The 
only option to assure their long-term maintenance is to transfer them to the Zebrafish 
International Resource Center (ZIRC) in the USA. Due to the difficulty of 
international shipping, future access of European researchers to these lines will be 
severely impaired. To prevent this loss for European research, EuFishBioMed lobbied 
successfully for support to build a European Zebrafish Resource Center (EZRC). This 
unique European infrastructure located at the Karlsruhe Institute of Technology, 
Karlsruhe, Germany has recently become operational and will closely collaborate 
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with ZIRC. In addition to maintaining and distributing zebrafish stocks, it will 
provide access to critical technology platforms (automated screening, high-throughput 
imaging, data storage, mapping and expression profiling). Thus, EZRC and ZIRC will 
complement each other in their services to the international community.  
 
The Future: The European Society for Fish Models in Biology and 
Medicine 
Although the administrative burden associated with a COST Action is 
enormous in relation to the allocated funds, there is general agreement among the 
scientists concerned that the EuFishBioMed COST Action (BM0804) has had a major 
impact on European research in this field. The establishment of a well-connected 
European zebrafish community with a common communication platform and resource 
centre has been critical to meet the specific needs of zebrafish researchers and their 
institutions. EuFishBioMed has become a platform for the realisation of new research 
projects dedicated to more specific clinical, industrial or regulatory needs. Most 
importantly, it has provided the tools to efficiently lobby for support without 
unnecessarily duplicating efforts in the complex European funding and regulatory 
landscape.  
 
EU COST Action funding will cease in 2013, raising the question of how to 
continue afterwards. To this end, at the occasion of the 2011 European Zebrafish 
Meeting in Edinburgh the EuFishBioMed management committee made a decision to 
found a charitable association. This association will be named the European Society 
for Fish Models in Biology and Medicine. It will not only maintain the acronym 
EuFishBioMed but hopefully also continue and expand the key services currently 
offered by EuFishBioMed, including its website, database and the organisation and 
sponsoring of workshops and meetings.  
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Table 1  Workshops and meetings supported by EuFishBioMed 
 
 
 
Title Location Date 
6
th 
European Zebrafish Genetics and 
Development Meeting, 
Rome,  
Italy 
 
15.-19.07.2009 
Disease Modelling in Zebrafish: Cancer and 
Immune Responses 
 
Spoleto,  
Italy 
 
20.-22.07.2009 
1st European Zebrafish PI Meeting 
 
Padua,  
Italy 
18.-21.03.2010 
 
In-vitro fertilization and cryo-preservation of 
sperm in medaka fish 
 
Karlsruhe,  
Germany 
 
29.-31.03.2010 
 
The zebrafish embryo model in toxicology and 
teratology 
Karlsruhe,  
Germany 
 
02.-03.09.2010 
Zebrafish as a neurophysiological and 
neurobehavioural model 
London,  
United Kingdom 
08.-09.09.2010 
 
BioImage Analysis Workshop Karlsruhe,  
Germany 
 
01.10.2010 
 
 “Cutting Edge Technologies in Biomedical 
Research”  
Karlsruhe,  
Germany 
04.-06.05.2011 
 
7
th
 European Zebrafish Development and 
Genetics Meeting  
 
Edinburgh,   
United Kingdom 
 
05.-09.07.2011  
 
Blood, Immunity, Cancer and Endothelium 
workshop “Zebrafish Disease Models 
(ZDM4)” 
Edinburgh,   
United Kingdom 
09.-11.07.2011 
“Zebrafish: an animal model in biomedical 
research” 
 
Utrecht,  
The Netherlands 
 
14.-15.11.2011 
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